Related Experiment Video
Updated: Jun 21, 2026
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
Hydrogel-based protein array for quantifying epidermal growth factor receptor activity in cell lysates
Gargi Ghosh1, Andrew G Lee, Sean P Palecek
1Department of Chemical and Biological Engineering, University of Wisconsin-Madison, 1415 Engineering Drive, Madison, WI 53706, USA.
Abstract:
Epidermal growth factor receptor (EGFR) signaling plays an important role in a majority of solid tumors, and therapeutics targeted against EGFR has demonstrated promise in slowing growth of these tumors. However, many of these drugs either have failed to reproduce promising preclinical model results in clinical settings or have been successful in only a subgroup of cancer patients due partly to incomplete assessment of EGFR status in cancer. A patient-customized, predictive diagnostic for the effects of specific anti-EGFR therapies may improve outcomes. Here we report the development of a hydrogel-based protein array for quantitative and reproducible determination of the activity of EGFR directly from cellular extracts. In this study, we used glutathione S-transferase-fused Eps15 (GST-Eps15) fusion proteins immobilized within a polyacrylamide hydrogel as a substrate for quantifying EGFR kinase activity from the extracts of EGFR-expressing cell lines. Significant EGFR up-regulation was detected in a mixture containing 7% EGFR-overexpressing cell lysate diluted in lysate from a cell line expressing low levels of EGFR. In addition, the GST-Eps15 protein array was capable of detecting inhibition of EGFR activity when incubated with different tyrosine kinase inhibitors. These findings establish the potential of this protein-acrylamide copolymer hydrogel array not only to evaluate EGFR status in cancer cell lysates but also to screen for the most promising therapeutics for individual patients and monitor treatment progression.
Insights
A new hydrogel protein array accurately measures epidermal growth factor receptor (EGFR) activity in cancer cells. This diagnostic tool can personalize anti-EGFR therapies and monitor treatment effectiveness for improved patient outcomes.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Epidermal growth factor receptor (EGFR) signaling is crucial in many solid tumors, with targeted therapies showing promise.
- Clinical success of anti-EGFR drugs is limited by incomplete assessment of EGFR status and variable patient response.
- Personalized diagnostics are needed to predict patient response to specific anti-EGFR therapies.
Purpose of the Study:
- To develop a hydrogel-based protein array for quantifying EGFR activity directly from cellular extracts.
- To establish a reproducible method for assessing EGFR status in cancer.
- To evaluate the potential for personalized anti-EGFR therapy selection and treatment monitoring.
Main Methods:
- Development of a polyacrylamide hydrogel array functionalized with glutathione S-transferase-fused Eps15 (GST-Eps15) fusion proteins.
- Quantification of EGFR kinase activity using the GST-Eps15 protein array with cell lysates.
- Incubation of the array with tyrosine kinase inhibitors to assess EGFR activity inhibition.
Main Results:
- The hydrogel array successfully quantified EGFR kinase activity in cellular extracts.
- Significant EGFR up-regulation was detected even in diluted samples.
- The array detected inhibition of EGFR activity by various tyrosine kinase inhibitors.
Conclusions:
- The developed protein-acrylamide copolymer hydrogel array is a promising tool for evaluating EGFR status in cancer.
- This array has the potential to guide the selection of optimal anti-EGFR therapeutics for individual patients.
- The array can also be utilized for monitoring treatment progression in cancer patients.
